A natural supplement previously only available in Europe, has been released in the United States to help millions of women with Polycystic Ovary Syndrome treatment (PCOS).

Approximately 10% of women between the ages of 14 and 40 have PCOS, a devastating combination of hormone imbalances that can lead to severe medical and reproductive difficulties including hypertension, obesity, hyperlipidemia, heart disease, insulin resistance, type II diabetes, breast cancer, uterine cancer, irregular menstrual cycles, acne, increased facial and body hair growth, difficulty conceiving, an increased risk of miscarriages, and pregnancy complications such as hypertension and gestational diabetes.

Scott Roseff, MD, FACOG, of the South Florida Institute for Reproductive Medicine (SFIRM), is a renowned fertility specialist and expert in the diagnosis and treatment of PCOS. Dr. Roseff investigated Pregnitude (Everett Labs, NJ), an all-natural supplement designed to address the deficiencies found in the ovaries of women plagued by PCOS, and found that it improved insulin resistance with the same effectiveness as prescription-only metformin but without metformin’s high incidence of side effects.

Women with fertility challenges ovulated on over-the-counter Pregnitude as frequently as patients taking prescription Clomid but were free of the adverse reactions and risks commonly known with Clomid.

Many patients undergoing IVF treatment were found to have better quality eggs and embryos after taking Pregnitude.

Pregnitude can benefit women and aid Polycystic Ovary Syndrome treatment as well as those suffering from various types of infertility. Pregnitude combines myo-inositol and folic acid and became available in U.S. pharmacies this month without a prescription.